NCT05675319 2026-01-05AlloRelapseMMUniversitätsklinikum Hamburg-EppendorfPhase 3 Terminated28 enrolled
NCT03411031 2023-03-29Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated18 enrolled 11 charts